Member Info for 86KB

Meeting was changed to 26th March so this Tgursday for vote.

Sec approval, mbo usually late with rns. Should get one after 12

Back to double digits. GLA

Much better spread 0.18 bid 0.222 ask, not much left at 0.222 before another tick up. GLA

Chunky buys went through just before 11 hence the jump.

This is going to go on a run today and continue going as we approach end of month. They let a few buyers in at 0.2 and back to NT again for any amount. GLA

Nothing of decent size available with IG I even tried 50k shares. Only 20k which is like £37 lol.

Few sellers but you still can't buy, must be some large order filling going on

I can sell but havnt been able to buy anything since first thing.

I can

How about you look at the daily chart and say what you think instead of the weekly.

I am sure Tim will address all questions people have tomorrow. Not sure why everyone thinks its doom and gloom just because they raised for another project. Know that some have always had an agenda here. Tim has clearly stated P140 deal is still being discussed. Like most I also expected the next rns to be a deal for P140 but its not as if talks have ended just more time is required and not according to our timing. 2 big assets for a pharma with less than £25m opportunity here imo.

Markets are generally down today due to whats going on but once things settle I am sure this will do its thing. If you no longer believe then sell up and move and those who never had any interest but to constantly talk this share down go get a life!

Looking good here today

Look back at last years rns they had the same issue as todays rns regarding delay/suspension for results. Different rules over in Australia. Within a week they released the results. No need for worry imo.

17 March 2026

Pyx Resources Limited – PYX (“the Company”)

Trading Halt

All securities in Pyx Resources Limited have been placed under an immediate Trading Halt as a result of the

Company failing to lodge their Preliminary Financial Statements for 31 December 2025, pursuant with Listing

Rule 2A, 6.11.

The Securities of the Company will be reinstated to official quotation once it has satisfied its obligations

according to the NSX Listing Rules.

3 April 2025

Pyx Resources Limited – PYX (“the Company”)

Suspension from Official Quotation

All securities in Pyx Resources Limited have been placed under suspension as a result of the Company

failing to lodge their Annual Financial Statements for 31 December 2024, pursuant with Listing Rule 2A,

6.8.

The Securities of the Company will be reinstated to official quotation once it has satisfied its

obligations according to the NSX Listing Rules.

For more information, please visit the NSX website www.nsx.com.au.

I am sure Tim will do an interview and explain everything in detail. Yes, annoying he did a placing after saying they didn't require it, however it was done at 6p and the current share price drop is way overdone. The deal for P140 is still on the cards regardless of what people thoughts are on this board. If it wasn't he would have to state it in the rns. No doubt we will get something for that soon. Have to remember Lanstead approached the company and perhaps Tim thought why not strengthen the balance sheet whilst discussions are taking place which will give them a better deal. Now they have two big assets all for a mcap less than £30m. Once the dust settles I am sure this will do its thing. GLA

Https://x.com/proactive_x/status/2033812090863935920?s=20

Little pharma company with now two major projects in high demanding markets, diabetes and autoimmune disease. With mcap less than £30m, you don't get many pharmas with such low mcaps with big assets. Certainly see these trading in £s at some point.

Just look at the market size and know what they are going to do is very good news for shareholders. Opportunity to buy around placing/just under.

The global type 1 diabetes market, valued at approximately $15.95–$16.01 billion in 2024, is projected to grow to over $24–$31 billion by 2031–2035

At the same time, I would like to reassure shareholders that P140 remains a core value driver for ImmuPharma. We continue to make good progress in detailed discussions with a number of potential partners and remain focused on completing a value‑enhancing licensing deal in 2026

Well volume already 2.5m in less than 15mins, won't be suprised to see this flat very quickly.